New England Peptide Adds Two Global Peptide Leaders to Advisory Board

Hodges, Hruby Both Headed American Peptide Society

Gardner, MA – New England Peptide, LLC, (NEP) has named Dr. Robert Hodges and Dr. Victor Hruby to its Scientific Advisory Board. From pain relief to vaccines and protein design to purification of peptide drugs, through their expertise and creativity Hodges and Hruby have impacted almost of every area of peptide and protein science in their more than 80 years of combined experience.

Hodges and Hruby both have served as president of the American Peptide Society (APS), which means, including Dr. Tomi Sawyer, NEP has three past presidents of the peptide industry’s top trade association advising the company.

“All of us at New England Peptide are excited to welcome Bob and Victor to our growing team of peptide experts,” said NEP CEO Dave Robinson.  “Not only are they two of the best peptide researchers in the business, but they have contributed greatly to the development of the peptide community through their leadership at APS.”

Hodges joins the SAB with a 35-year reputation as a peptide research expert. He is currently the Director of the Program in Biomolecular Structure, Professor of Biochemistry and Molecular Genetics at the University of Colorado, Denver School of Medicine, where he holds the John Stewart Chair in Peptide Chemistry.  In 2002, he won the Vincent Du Vigneaud Award from the American Peptide Society for outstanding achievements in peptide research. He also worked under Dr. Bruce Merrifield, the American biochemist who won the 1984 Nobel Prize in chemistry for the invention of solid phase peptide synthesis.  Hodges earned his Ph.D. in Biochemistry from the University of Alberta.  

Hruby, a leading academic figure in peptide research, is Regents Professor in the Department of Chemistry at the University of Arizona. Hruby has published more than 1000 articles, reviews, chapters, commentaries and editorials and has over 25 patents and patent filings. He has received numerous awards and honors, including the 1993 Alan E. Pierce Award (now the Merrifield Award).  Hruby received his B.S. and M.S. at the University of North Dakota and then earned his Ph.D. at Cornell University under A. T. Blomquist.  After earning his Ph.D, Hruby became an Instructor at Cornell University Medical College with Nobel Prize winner Vincent duVigneaud.

The other members of the SAB are Dr. Tomi Sawyer, who is chief science officer of Aileron Therapeutics, and Dr. Vincent Bille, who is founder and principal of Brussels-based Marble Pharma Consulting.  Another member of the SAB, Dr. Ved Srivastava, left the board to become NEP’s vice president for research production.

“Our SAB has a great balance of university and industry expertise over a wide variety of peptide areas,” said Robinson.  “We anticipate that with their guidance we will be able to grow the company and improve on our proven track record of delivering first rate service to our customers.”

About New England Peptide (

New England Peptide, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use. All segments of the peptide market – from therapeutics and vaccines to diagnostics and cosmetics – are thriving.



"THANKS AGAIN for all the intellectual support that NEP has provided to us over the last year. My colleagues have been overwhelmingly impressed with the quality of service and level of thought that you have put into researching and thinking about our particular peptide and antibody production needs. The level of scholarship went well beyond what we expected from any peptide and antibody company, and was crucial in shaping our decisions. It has truly been a pleasure corresponding with you."
Cliff N. PhD - Lawrence Berkeley National Laboratory